Hodgkin's disease, 7 of unrelated causes and 2 of second malignancy. A further 3 patients who developed second malignancy are still alive. At 15 years the actuarial mortality related to HD was 12%. These results confirm the importance of long follow up to assess the efficacy of primary therapy.
Finzi suggested, from St Bartholomew's Hospital, in 1913 that extending the irradiation field beyond that required to encompass the involved nodes to include contiguous areas might improve the prognosis of localised Hodgkin's disease (HD). This view was supported by Gilbert (1939) , Craft (1940) , Peters (1950 Peters ( , 1958 , Easson (1963) , and particularly reinforced by Kaplan (1962) , such that extended field megavoltage radiotherapy, has become the accepted treatment of choice, for patients with localised HD to this present day. The techniques available for determining the extent of HD have improved considerably during the past thirty years, with lymphangiography and latterly computerised axial tomography (CAT) for delineating intra-abdominal lymph nodes, and laparotomy in selected instances for detecting splenic and hepatic involvement. This has inevitably led to greater precision of staging, and hence, possibly to an apparent improvement in the results of radiotherapy for localised HD.
The results presented below demonstrate what may be achieved with a uniform policy of mantle radiotherapy for supradiaphragmatic and inverted 'Y' for infradiaphragmatic stage I HD. All cases were documented with lymphangiography or CAT scanning, and in the majority with staging laparotomy. This report extends upon the previously published observations (Timothy et al., 1978 second remission after relapse was estimated from the date of re-evaluation after completion of therapy. Statistical significance was determined using the log rank method (Peto et al., 1977) .
Results

Overall
Complete remission was achieved in all 101 patients ( Figure  1 ). Eighty-two are still alive with a median follow up of 12 years ( Figure 2 ). Nineteen are dead, 6 from recurrent HD, 3 from second malignancy, 2 from infection and 8 from unrelated causes. The overall results were the same for those treated with mantle or inverted 'Y' radiotherapy as for those with protocol violations, but the results of the former group have been analysed separately in detail to give information about that specific therapy. Figure 3) . By univariate analysis the duration of remission was significantly longer for surgically staged patients as opposed to clinically staged patients (Figure 4 , P = 0.02). The pattern of relapse was different between CS and PS patients (Table III) with more relapses occurring outside the radiation field in the former group, though it was not statistically significant (P = 0.08). Overall, lymphadenopathy recorded as greater than 3 cm correlated adversely with duration of remission ( Figure 7 ).
There was no correlation between the dose of radiation with site or frequency of relapse.
Survival from presentation Seventy-four of the 90 patients are still alive, the remainder having died between 3 and 18 years ( Figure 8) . None of the prognostic factors analysed for duration of remission correlated with survival. Sixteen patients have died, 6 of progressive HD after relapse, one of septicaemia following therapy for relapse, 2 of second malignancy (Non-Hodgkin's lymphoma, carcinoma of the bronchus) and 7 of unrelated causes. The predicted cause-specific survival was 90% at 15 years ( Figure 9 ). Survivalfrom relapse Eight of the 18 patients who relapsed are alive, the remaining 10 having died within 5 years ( Figure  10 ). Second malignancy and 'complications' Five patients have developed a second malignancy at least 1 year from completion of therapy. It has been fatal, to date, in two (Table  IV) . There was no post splenectomy septicaemia in this group of patients. No major complications of radiotherapy were observed. Patients with protocol violations One of the 11 patients has relapsed and is in second remission. Two have died, 1 of carcinoma of the bronchus and the other due to infection and diabetes mellitus (Table I) . was the same for those undergoing laparotomy as for those (Years) treated on the basis of clinical stage, the pattern of life for val of 90 patients with stage I these two groups was different, since the latter had a much higher requirement for multiple therapy. The significance of the five instances of second malignancy is as yet unclear, particularly since half of them were common and might have occurred by chance. Longer follow-up, N = 90 and extrapolation from other series will be required to determine whether there will be more and different, second cancers in patients receiving multiple therapy as opposed to radiotherapy alone (Kaldor et al., 1990; Henry-Amar, 1983 ).
The results are comparable with the published literature, if it is assumed that this patient population corresponds with that of the most favourable localised Hodgkin's disease reported by others (Hoppe et al., 1982; Cornbleet et al., 1985; Fuller et al., 1980; Tubiana et al., 1985; Mauch et al., 1988; Hagemeister et al., 1982 (Carde et al., 1988) . It is further corroborated by the results reported from Boston wherein staging laparotomy was consistently performed with mantle, paraortic and splenic irradiation in stage I HD (Mauch et al., 1988) . Although involved field irradiation alone has been reported to result in the same survival at 10 years, this approach accepts an increased relapse rate and the necessity of subsequent treatment. The poor outcome of the patients who relapsed in our series call this approach into question (Stoffel et al., 1977; Rosenberg & Kaplan, 1985; Collaborative Study, N -18 1984) . effective without increase in short term toxicity. For most centres this has been limited to extending the mantle field down the paraortic chain. The H6 EORTC trial (Tubiana et al., 1989) has, however, reintroduced splenic irradiation for clinically staged patients comparing it with laparotomy and mantle irradiation for 'favourable' patients, both yielded similar results at 4 years. Longer follow-up will determine whether there is a greater morbidity or mortality with the larger radiation field (Sutcliffe et al., 1985) .
The choice of therapy is also determined by the potential complications of laparotomy, namely, overwhelming sepsis (Coker et al., 1983) , possible contribution towards the development of secondary leukaemia (Van Leeuwen et al., 1987) , and delay in instituting radiation therapy. More data are becoming available to provide accurate predictions of the likely outcome of the operations in relation to presentation variables (Leibehaut et al., 1989; Tubiana et al., 1989) , which may lessen the dilemma.
The above results confirm the good progress of stage I HD treated by primary radiotherapy. It is notable, however, that an appreciable risk of relapse persists up to 9 years after therapy and therefore prolonged follow up is essential. Furthermore, 1 in 3 of patients who relapsed subsequently died of HD. While it may be possible to reduce therapy for selected patients at presentation, thereby also reducing toxicity, considerable thought must be given to those who relapse. Particular attention must be given to defining the criteria for proceeding to therapy requiring bone-marrow rescue.
